Print
Email
Print Edition StoriesMonday, March 17, 2008
PSivida could see $78M from Alimera deal changes
Biotech firm pSivida Ltd. reports amending a license to its experimental treatment for diabetic macular edema (DME) with Alimera Sciences Inc.
PSivida (Nasdaq: PSDV), an Australian firm with U.S. offices in Watertown, said that Atlanta-based Alimera has increased its stake in future profits of the DME treatment, Medidur FA, from 50 percent to 80 percent in exchange for $78 million in initial and future payments to pSivida.
In October 2007, Alimera completed enrollment in a 956-patient, Phase 3 study of Medidur to treat DME, a disease involving retinal thickening that is the leading cause of adult blindness in developed countries.
PSivida, which develops nanostructured silicon for drug delivery and other uses, reported a 2007 net loss of $92.1 million, on revenue $2.5 million. The firm lists 26 employees.
Comments
If you are commenting using a Facebook account, your profile information may be displayed with your comment depending on your privacy settings. By leaving the 'Post to Facebook' box selected, your comment will be published to your Facebook profile in addition to the space below.
RSS Feeds
